118
Participants
Start Date
April 15, 2024
Primary Completion Date
December 31, 2027
Study Completion Date
June 30, 2028
anti-CD25 rhMAb
1 mg/kg/day administered IV day 1, 4, and 8, then weekly for 6 doses. For patients achieving partial remission, an extra dose of Anti-CD25 rhMAb can be given on days 39 and 49.
Prednisone
Maintain pre-screening dose
Ruxolitinib
10mg, BID PO
Cyclosporine
1.25mg/kg, BID PO/IV, target:150-250ng/ml
Peking University People's Hospital
OTHER